Citius Pharmaceuticals (NASDAQ:CTXR – Get Free Report) and PainReform (NASDAQ:PRFX – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, dividends, earnings, profitability and institutional ownership.
Insider & Institutional Ownership
16.9% of Citius Pharmaceuticals shares are held by institutional investors. Comparatively, 37.3% of PainReform shares are held by institutional investors. 10.7% of Citius Pharmaceuticals shares are held by insiders. Comparatively, 34.4% of PainReform shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Analyst Ratings
This is a summary of current ratings and target prices for Citius Pharmaceuticals and PainReform, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Citius Pharmaceuticals | 1 | 2 | 1 | 0 | 2.00 |
| PainReform | 1 | 0 | 0 | 0 | 1.00 |
Risk and Volatility
Citius Pharmaceuticals has a beta of 1.56, meaning that its share price is 56% more volatile than the S&P 500. Comparatively, PainReform has a beta of 0.59, meaning that its share price is 41% less volatile than the S&P 500.
Earnings and Valuation
This table compares Citius Pharmaceuticals and PainReform”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Citius Pharmaceuticals | N/A | N/A | -$37.43 million | ($3.37) | -0.25 |
| PainReform | N/A | N/A | -$14.59 million | ($147.33) | -0.01 |
Citius Pharmaceuticals is trading at a lower price-to-earnings ratio than PainReform, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Citius Pharmaceuticals and PainReform’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Citius Pharmaceuticals | N/A | -55.93% | -31.00% |
| PainReform | N/A | N/A | N/A |
Summary
PainReform beats Citius Pharmaceuticals on 6 of the 11 factors compared between the two stocks.
About Citius Pharmaceuticals
Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.
About PainReform
PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel.
Receive News & Ratings for Citius Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Citius Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
